Company / Depreciation & Amortization
Inhibrx Biosciences, Inc. Depreciation & Amortization History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$2.5M
FY2025
5-year range
$1.2M / $2.5M
FY2023-FY2025
Trend
+108.5%
vs FY2024
Sector context
#95 of 168
Health Care
What the data says
At $2M, Inhibrx Biosciences, Inc.'s depreciation & amortization ranks #74 of 168 in the Health Care sector. Increased from $1M to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2025.
Increased from $1M to $2M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#74 of 168 in Health CareTop 43% of 168This company $2.5M Sector average $212.9M
▼
-98.8% below sector average
Key checks
Key Insights
- In FY2025, depreciation & amortization increased 108.5% year-over-year.
- Ranks #95 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.5M | +108.5% |
| FY2024 | $1.2M | +0.0% |
| FY2023 | $1.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026